This observational study intends to retrospectively gather information on cytomegalovirus (CMV) infection management in the United Kingdom (UK) over a period of 7 years (2017-2024). The main aims of this study are the following: * To estimate the overall prevalence and annual rate of adults with refractory CMV infection after a kidney transplant and describe how such CMV infections are treated * To describe how effective and well-tolerated the treatment was. * To describe the demographic and clinical characteristics of adult participants with CMV infection (refractory and non-refractory). In this study, already existing data will be reviewed and analysed from a UK database called the Registry of Rare Kidney Diseases (RaDaR) (NCT06065852). The study will only review data collected as part of routine clinical practice. The study will not impact the standard medical care and treatment of participants.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants With Non-Refractory and Refractory CMV Post-Kidney Transplant in 2024
Timeframe: 1 year
Number of New Non-Refractory and Refractory CMV Cases per Year
Timeframe: 7 years
Percentage of Participants Given Prophylaxis at the Time of Kidney Transplant
Timeframe: At the time of kidney transplant (up to 7 years)
Distribution of Drugs Prescribed for Prophylaxis
Timeframe: Up to 7 years
Duration of Prophylactic Treatment
Timeframe: Up to 7 years
Dose of Prophylactic Treatment
Timeframe: Up to 7 years
Distribution of Drugs Prescribed for Initial Anti-CMV Treatment
Timeframe: Up to 7 years
Duration of Initial Anti-CMV Treatment
Timeframe: Up to 7 years
Dose of Initial Anti-CMV Treatment
Timeframe: Up to 7 years
Distribution of Drugs Prescribed as Anti-CMV Treatment Subsequent to Initial Therapy in Participants With Refractory CMV
Timeframe: Up to 7 years
Duration of Time on Anti-CMV Treatment Subsequent to Initial Anti-CMV Therapy
Timeframe: Up to 7 years
Dose of Anti-CMV Treatment Subsequent to Initial Anti-CMV Therapy
Timeframe: Up to 7 years
Percentage of Participants With Refractory CMV Who Switched Type of Anti-CMV Treatment Subsequent to Initial Therapy in Six-Month Follow up Period
Timeframe: 6 months follow up period from index date
Time to Switch of Drug for Anti-CMV Treatment Subsequent to Initial Therapy
Timeframe: Up to 7 years
Number of Switches per Participants in Six-Month Follow up Period
Timeframe: 6 months follow up period
Number of Participants as per Positioning of Marabivir in the Treatment Pathway
Timeframe: Up to 7 years
Percentage of Participants With Viral Clearance During the Follow up Period
Timeframe: 6 months follow up period
Time to Viremia Recurrence From Documented Clearance or Cessation of Anti-CMV Treatment
Timeframe: Up to 7 years
Percentage of Participants With Recurrence of CMV Infection
Timeframe: Up to 7 years
Number of Hospital Admissions (per Year and Overall)
Timeframe: Up to 7 years
Reasons for Hospital Admission
Timeframe: Up to 7 years
Number of Hospitalisations (Including Intensive Care) per Participant in Six-Month Follow up Period
Timeframe: 6 months of follow up period
Duration of Hospitalisation
Timeframe: Up to 7 years
Number of Outpatient Visits in Six-month Follow up Period
Timeframe: 6 months of follow up period
Percentage of Participants With Graft Loss in Six-month Follow up Period
Timeframe: 6 months of follow up period from index date
Number of Occurrences of Each Reason for Graft Loss Listed in the Registry
Timeframe: Up to 7 years
Percentage of Participants With Graft Loss Over Time for Refractory Versus non-Refractory Group
Timeframe: Up to 7 years
Number of Participants Who Died
Timeframe: Up to 7 years
Time to Death From Index Date/Transplant Date
Timeframe: From Index date/transplant date up to 7 years
Number of Mortality (All-cause Death)
Timeframe: Up to 7 years
Number of Participants With Reasons for Mortality
Timeframe: Up to 7 years
Change in Renal Function (Estimated Glomerular Filtration Rate [eGFR]) From Index Date to Six-month Follow up
Timeframe: From index date to 6 months of follow up period
Change in White Cell Count (Neutrophils) From Index Date to Six-month Follow up
Timeframe: From index date to 6 months of follow up period
Percentage of Participants with Diabetes, Hypertension, and Cardiovascular Disease at the Time of Transplant
Timeframe: At the time of transplant (up to 7 years)